© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 22, 1812-1818,
November 17, 1993
© 1993 Oxford University Press
Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor 
Induction In Vivo
Imperial Cancer Research Fund Clinical Oncology Unit, Churchill Hospital Oxford, England
Biological Therapy Laboratory, Imperial Cancer Research Fund, Lincoln's Inn Fields London, England
Cancer Research Institute, Arizona State University, Tempe. Cancer Research Campaign Phase I Committee London, England
Correspondence to: Adrian L. Harris, B.Sc., M.A. D.Phit., F.R.C.P., ICRF Ctinical Oncology Unit, Churchill Hospital, Oxford OX3 7LJ. England
Background: Many oncogenes have been shown to code for growth factor receptors that are involved in regulation of cell growth and proliferation and can activate transcription via protein kinase C. Bryostatin 1, a partial agonist of protein kinase C, has demonstrated potent antitumor activity in vitro and in vivo in human tumor xenografts. Purpose: The aim of this phase I study was to determine the optimal dosage and toxicity profile of bryostatin 1 and its influence on cytokine release in vivo. Methods: Three successive cohorts consisting of 35 patients with various malignant tumors were treated with bryostatin 1 by intravenous infusion over 1 hour as follows: cohort A—35 µg/m2(three patients) or 50 µg/m2 (eight patients) once every 2 weeks; cohort B—25 µg/m2 once a week (eight patients); and cohort C—25 µg/m2 once a week for 3 weeks, with no treatment during the 4th week (16 patients). Plasma levels of tumor necrosis factor a (TNF-
) and interleukin 6 (IL-6) were measured by immunoradiometric assay and by radioimmunoassay, respectively. Results: The dose-limiting toxicity was grade 3 or 4 myalgia in four of 11 patients in cohort A, in two of wight in cohort B, and in none of 16 in cohort C. Occurrence of myalgia was dose related. There was no significant myelosuppression, apart from a small and transient fall in platelet count. Six patients experienced acute but transient skin flushing, dyspnea, hypotension, and bradycardia, probably related to the bryostatin 1 vehicle. TNF- and IL-6 were detected in plasma at 2 and 24 hours after treatment, respectively, and the levels were dose related (P =.02). Two patients with metastatic malignant melanoma had partial remission after three or four cycles of therapy; remission lasted 6 weeks and 10+ months, respectively. Conclusions: The dose-limiting toxicity of bryostatin 1 was myalgia. Plasma IL-6 and TNF- concentrations were increased within 24 hours of therapy. Antitumor activity against malignant melanoma was observed early in the course of treatment. Implications: The recommended dosage of bryostatin 1 for phase II studies is 25 µg/m2 by intravenous infusion for 1 hour once a week for 3 weeks, with no treatment in the 4th week. IL-6 and TNF- plasma concentrations may be useful in monitoring biological activity of bryostatin 1. Future studies should explore use of this drug with other conventional immune modulators and conventional cytotoxic drugs. [J Natl Cancer Inst 85: 1812–1818, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. F. El-Rayes, S. Gadgeel, A. F. Shields, S. Manza, P. Lorusso, and P. A. Philip Phase I Study of Bryostatin 1 and Gemcitabine Clin. Cancer Res., December 1, 2006; 12(23): 7059 - 7062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Roberts, M. R. Smith, E. J. Feldman, L. Cragg, M. M. Millenson, G. J. Roboz, C. Honeycutt, R. Thune, K. Padavic-Shaller, W. H. Carter, et al. Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma. Clin. Cancer Res., October 1, 2006; 12(19): 5809 - 5816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Li, W. Wojciechowski, C. Dell'Agnola, N. E. Lopez, and I. Espinoza-Delgado IFN-{gamma} and T-bet Expression in Human Dendritic Cells from Normal Donors and Cancer Patients Is Controlled through Mechanisms Involving ERK-1/2-Dependent and IL-12-Independent Pathways J. Immunol., September 15, 2006; 177(6): 3554 - 3563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Schwartz and M. A. Shah Targeting the Cell Cycle: A New Approach to Cancer Therapy J. Clin. Oncol., December 20, 2005; 23(36): 9408 - 9421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wojciechowski, H. Li, S. Marshall, C. Dell'Agnola, and I. Espinoza-Delgado Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms J. Immunol., June 15, 2005; 174(12): 7859 - 7868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Do, V. L. Hegde, P. S. Nagarkatti, and M. Nagarkatti Bryostatin-1 Enhances the Maturation and Antigen-Presenting Ability of Murine and Human Dendritic Cells Cancer Res., September 15, 2004; 64(18): 6756 - 6765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Amador, J. Jimeno, L. Paz-Ares, H. Cortes-Funes, and M. Hidalgo Progress in the development and acquisition of anticancer agents from marine sources Ann. Onc., November 1, 2003; 14(11): 1607 - 1615. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wang, Z. Wang, P. Dent, and S. Grant Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells Blood, May 1, 2003; 101(9): 3648 - 3657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Messmann, C. D. Ullmann, T. Lahusen, A. Kalehua, J. Wasfy, G. Melillo, I. Ding, D. Headlee, W. D. Figg, E. A. Sausville, et al. Flavopiridol-related Proinflammatory Syndrome Is Associated with Induction of Interleukin-6 Clin. Cancer Res., February 1, 2003; 9(2): 562 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. B. Haas, M. Smith, N. Lewis, L. Littman, G. Yeslow, I. D. Joshi, A. Murgo, J. Bradley, R. Gordon, H. Wang, et al. Weekly Bryostatin-1 in Metastatic Renal Cell Carcinoma: A Phase II Study Clin. Cancer Res., January 1, 2003; 9(1): 109 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Cragg, M. Andreeff, E. Feldman, J. Roberts, A. Murgo, M. Winning, M. B. Tombes, G. Roboz, L. Kramer, and S. Grant Phase I Trial and Correlative Laboratory Studies of Bryostatin 1 (NSC 339555) and High-Dose 1-B-D-Arabinofuranosylcytosine in Patients with Refractory Acute Leukemia Clin. Cancer Res., July 1, 2002; 8(7): 2123 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Otieno, C. Banura, E. Katongole-Mbidde, J. L. Johnson, M. Ghannoum, A. Dowlati, R. Renne, E. Arts, C. Whalen, M. M. Lederman, et al. Therapeutic Challenges of AIDS-Related Non-Hodgkin's Lymphoma in the United States and East Africa J Natl Cancer Inst, May 15, 2002; 94(10): 718 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Curiel, C. S. Garcia, L. Farooq, M. F. Aguero, and I. Espinoza-Delgado Bryostatin-1 and IL-2 Synergize to Induce IFN-{gamma} Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy J. Immunol., November 1, 2001; 167(9): 4828 - 4837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Zonder, A. F. Shields, M. Zalupski, R. Chaplen, L. K. Heilbrun, P. Arlauskas, and P. A. Philip A Phase II Trial of Bryostatin 1 in the Treatment of Metastatic Colorectal Cancer Clin. Cancer Res., January 1, 2001; 7(1): 38 - 42. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Koutcher, M. Motwani, K. L. Zakian, X.-K. Li, C. Matei, J. P. Dyke, D. Ballon, H. H. Yoo, and G. K. Schwartz The in Vivo Effect of Bryostatin-1 on Paclitaxel-induced Tumor Growth, Mitotic Entry, and Blood Flow Clin. Cancer Res., April 1, 2000; 6(4): 1498 - 1507. [Abstract] [Full Text]
|
|
|
|
|
|
M. Garzotto, A. Haimovitz-Friedman, W.-C. Liao, M. White-Jones, R. Huryk, W. D. W. Heston, C. Cardon-Cardo, R. Kolesnick, and Z. Fuks Reversal of Radiation Resistance in LNCaP Cells by Targeting Apoptosis through Ceramide Synthase Cancer Res., October 1, 1999; 59(20): 5194 - 5201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Weitman, A.-M. Langevin, R. L. Berkow, P. J. Thomas, C. A. Hurwitz, A. S. Kraft, R. L. Dubowy, D. L. Smith, and M. Bernstein A Phase I Trial of Bryostatin-1 in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study Clin. Cancer Res., September 1, 1999; 5(9): 2344 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Gelmon, E. A. Eisenhauer, A. L. Harris, M. J. Ratain, and P. Workman Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug Development? J Natl Cancer Inst, August 4, 1999; 91(15): 1281 - 1287. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Propper, M. P. Saunders, A. J. Salisbury, L. Long, K. J. O'Byrne, J. P. Braybrooke, M. Dowsett, M. Taylor, D. C. Talbot, T. S. Ganesan, et al. Phase I Study of the Novel Cyclic AMP (cAMP) Analogue 8-Chloro-cAMP in Patients with Cancer: Toxicity, Hormonal, and Immunological Effects Clin. Cancer Res., July 1, 1999; 5(7): 1682 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Matthews, G. R. Pettit, and E. Rozengurt Bryostatin 1 Induces Biphasic Activation of Protein Kinase D in Intact Cells J. Biol. Chem., August 8, 1997; 272(32): 20245 - 20250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Bosco, S. Rottschafer, L. S. Taylor, J. R. Ortaldo, D. L. Longo, and I. Espinoza-Delgado The Antineoplastic Agent Bryostatin-1 Induces Proinflammatory Cytokine Production in Human Monocytes: Synergy With Interleukin-2 and Modulation of Interleukin-2Rgamma Chain Expression Blood, May 1, 1997; 89(9): 3402 - 3411. [Abstract] [Full Text] [PDF]
|
|